Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To investigate PK and coagulating and fibrinolytic parameter profiles (PD) at the approved
dose (13,750 - 27,500 IU/kg) in patients with acute pulmonary embolism accompanying
hemodynamic instability.